Catalyst Pharmaceuticals (CPRX) Competitors $20.08 -0.17 (-0.86%) As of 11:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CPRX vs. MRNA, ELAN, VRNA, ROIV, RVMD, GRFS, ABVX, RYTM, AXSM, and LEGNShould you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Abivax (ABVX), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Catalyst Pharmaceuticals vs. Its Competitors Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Grifols Abivax Rhythm Pharmaceuticals Axsome Therapeutics Legend Biotech Moderna (NASDAQ:MRNA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do analysts recommend MRNA or CPRX? Moderna currently has a consensus target price of $42.88, suggesting a potential upside of 69.74%. Catalyst Pharmaceuticals has a consensus target price of $33.20, suggesting a potential upside of 65.37%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Catalyst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Do institutionals & insiders have more ownership in MRNA or CPRX? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is MRNA or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 37.36% compared to Moderna's net margin of -94.31%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Catalyst Pharmaceuticals 37.36%40.78%35.36% Which has more volatility and risk, MRNA or CPRX? Moderna has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Does the media refer more to MRNA or CPRX? In the previous week, Moderna had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 17 mentions for Moderna and 15 mentions for Catalyst Pharmaceuticals. Moderna's average media sentiment score of 1.03 beat Catalyst Pharmaceuticals' score of 0.83 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Catalyst Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, MRNA or CPRX? Catalyst Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.04-$3.56B-$7.53-3.35Catalyst Pharmaceuticals$491.73M5.00$163.89M$1.6512.17 SummaryCatalyst Pharmaceuticals beats Moderna on 11 of the 17 factors compared between the two stocks. Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPRX vs. The Competition Export to ExcelMetricCatalyst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.46B$2.55B$5.80B$10.16BDividend YieldN/A56.65%5.69%4.61%P/E Ratio12.1823.4774.7325.99Price / Sales5.00554.82470.3491.76Price / Cash8.07169.2537.0859.91Price / Book3.295.3712.256.31Net Income$163.89M$32.95M$3.28B$270.66M7 Day Performance-1.05%2.18%1.39%3.52%1 Month Performance-1.30%9.45%7.70%6.79%1 Year Performance-1.05%1.25%64.01%28.29% Catalyst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPRXCatalyst Pharmaceuticals4.9211 of 5 stars$20.08-0.9%$33.20+65.4%+4.1%$2.46B$491.73M12.1880Positive NewsInsider TradeMRNAModerna4.5215 of 5 stars$24.83-1.2%$42.88+72.7%-68.1%$9.66B$3.24B-3.305,800Positive NewsELANElanco Animal Health2.6536 of 5 stars$19.02+3.2%$17.33-8.9%+29.8%$9.45B$4.44B22.129,000VRNAVerona Pharma PLC American Depositary Share2.1761 of 5 stars$106.300.0%$109.00+2.5%+252.9%$9.19B$42.28M-107.3730Positive NewsROIVRoivant Sciences2.8286 of 5 stars$12.91-0.1%$16.38+26.8%+16.4%$8.82B$23.23M-18.44860News CoverageOptions VolumeRVMDRevolution Medicines4.2667 of 5 stars$41.06+1.4%$72.00+75.4%+11.0%$7.68B$11.58M-9.12250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.9747 of 5 stars$10.11-0.2%$10.30+1.9%+9.0%$6.95B$7.81B8.6423,822News CoveragePositive NewsABVXAbivax2.3345 of 5 stars$90.00+2.2%$92.33+2.6%+631.6%$6.80BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownHigh Trading VolumeRYTMRhythm Pharmaceuticals3.1774 of 5 stars$99.77-2.3%$101.57+1.8%+98.6%$6.63B$130.13M-33.15140Positive NewsAXSMAxsome Therapeutics4.9162 of 5 stars$129.29+3.3%$177.86+37.6%+35.1%$6.45B$385.69M-25.50380Positive NewsInsider TradeLEGNLegend Biotech3.2956 of 5 stars$34.62-4.0%$74.22+114.4%-32.0%$6.39B$627.24M-39.342,609Positive News Related Companies and Tools Related Companies MRNA Alternatives ELAN Alternatives VRNA Alternatives ROIV Alternatives RVMD Alternatives GRFS Alternatives ABVX Alternatives RYTM Alternatives AXSM Alternatives LEGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CPRX Stock Alerts